<DOC>
	<DOCNO>NCT01875926</DOCNO>
	<brief_summary>The overall aim study : - To provide additional information pharmacokinetics ALX-0171 measuring ( ) local ( bronchoalveolar lavage fluid ( BALF ) ) systemic ( plasma ) concentration ALX-0171 oral inhalation , ( ii ) systemic ( plasma ) urine concentration intravenous administration . - To determine safety local systemic tolerability ALX-0171 . - To evaluate local ( induced sputum ) and/or systemic ( serum ) immunogenicity ALX-0171 , analyse potential occurrence anti-drug antibody ( ADA ) .</brief_summary>
	<brief_title>ALX-0171 Phase I Pharmacokinetic Study Healthy Male Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Respiratory Syncytial Virus Infections</mesh_term>
	<criteria>1 . Nonsmoking healthy male volunteer , ( 1855 year , extremes include ) . 2 . Good health condition , determine medical history , physical examination clinical laboratory test 3 . Body mass index ( BMI ) within normal range : 18.0 ≤ BMI &lt; 30.0 ( kg/m2 ) 4 . Haematology chemistry parameter within normal range , show clinically relevant deviation ( judged Investigator ) 5 . Heart rate and/or blood pressure within normal range ( judged Investigator ) 6 . Electrocardiogram ( ECG ) within normal range , show clinically relevant deviation ( judged Investigator ) 7 . Negative urine test select drug abuse screen 8 . Negative alcohol breath test upon checkin study unit 9 . Negative hepatitis panel ( include hepatitis B surface antigen ( HBsAg ) antihepatitis C virus antibody ( antiHCV ) ) , negative human immunodeficiency virus ( HIV ) antibody screen 10 . Willingness consent use effective contraceptive method ( use 2 method contraception combination female partner : least 1 contraception method must barrier contraception method , e.g. , condom ) study least 3 month last study drug administration 11 . Ability comprehend willingness sign Informed Consent Form ( ICF ) For oral inhalation : 12 . Lung function test show Forced Expiratory Volume 1 second ( FEV1 ) ≥ 90 % predict value 13 . Ability retrobreathe nebulizer 14 . Height 170 190 cm ( extremes include ) 15 . Ability produce sufficient amount induce sputum ( least 400 μL contain visual sputum plug ) assess immunogenicity 1 . Current smoker , exsmokers abstinent tobacco le one year , history smoking 10 pack year 2 . Symptomatic viral infection , suspicion thereof ( include rhinitis ) last 14 day prior dose 3 . Signs active pulmonary infection pulmonary inflammatory condition , even absence febrile episode , last 14 day prior dose 4 . History presence disease kidney and/or heart , lung , liver , gastrointestinal tract , endocrine organ condition metabolic disease know interfere absorption , distribution , metabolism excretion drug 5 . Malignancy , prior malignancy , diseasefree interval &lt; 5 year diagnosis intervention , except basal cell carcinoma ( treat curatively ) 6 . Autoimmune disorder ( limit ) lupus erythematosus , multiple sclerosis , rheumatoid arthritis , sarcoidosis . 7 . History hypersensitivity allergy drug compound , include constituent ALX0171 8 . History previous administration ALX0171 , inhale biologic drug target Respiratory Syncytial Virus ( RSV ) F protein . In case use biologics : least 6 month administration first study medication , time duration pharmacodynamic effect , 10 time halflife respective drug , whatever longer 9 . Receipt investigational drug within 60 day prior dose 10 . Intake prescribed overthecounter medication within 14 day prior dose ( ≤ 3 g/day paracetamol allow ) 11 . History presence alcohol drug abuse 12 . Blood donation ( &gt; 500 mL ) comparable blood loss within three month prior dose 13 . Planned donation germ cell , blood , organ , bone marrow course study within 6 month thereafter 14 . Any condition prior therapy , opinion Investigator , would make subject unsuitable study 15 . Vulnerable subject ( e.g. , person keep detention ) For oral inhalation : 16 . History presence atopy condition associate airway hyperresponsiveness ( e.g. , allergic nonallergic asthma , chronic obstructive pulmonary disease ( COPD ) ) 17 . FEV1 drop &gt; 10 % inhalation 4 mL ALX0171 placebo ( measure 5 min end inhalation ) 18 . Contraindication sputum induction , ( limit ) recent eye surgery , recent fracture ribs recent ( history ) pneumothorax</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>